Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof

a technology antigen receptors, which is applied in the field of nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule, can solve the problems of limited and limited approach to adopting immunotherapy, and achieve the effect of enhancing the allogenicity of enhancing the genetically modified human t cell

Inactive Publication Date: 2020-10-29
PRECISION BIOSCI INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a method of genetically modifying human T cells to reduce the expression of cell surface proteins and make them less likely to be rejected by the body's immune system. This can be useful for creating new immune cells for use in treating cancer or other diseases. The method also reduces the allogenicity of the genetically-modified T cells, making them safer for use in humans.

Problems solved by technology

Despite its potential usefulness as a cancer treatment, adoptive immunotherapy has been limited, in part, by alloreactivity between host tissues and allogeneic CAR T cells.
However, complete knockout of beta-2 microglobulin expression may result in NK cell killing of CAR T cells due to the lack of cell surface MHC class I molecules, which could prompt NK cells to recognize them as non-self and initiate cytotoxic action.
An autologous approach provides immune tolerance to the administered CAR T cells; however, this approach is constrained by both the time and expense necessary to produce patient-specific CAR T cells after a patient's cancer has been diagnosed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
  • Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
  • Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

NK Cell Killing of B2M Knockout Primary Human T Cells

1. Methods and Materials

[0300]Primary human T cells were stimulated for 3 days using ImmunoCult anti-CD2 / CD3 / CD28 (StemCell Technologies) in the presence of IL-2 (Gibco) in XVIVO-15 medium (Lonza) supplemented with 5% fetal bovine serum. RNA encoding B2M13-14x479 nuclease was introduced into the T cells using the 4D Nucleofector (Lonza). Cells were cultured in the presence of IL-2 for 6 days before magnetic depletion of remaining B2M+ cells using biotinylated anti-human B2M (BioLegend) and a Biotin Selection Kit (StemCell Technologies). NK cells were isolated from PBMC samples of the same donor using a CD56 positive selection kit (StemCell Technologies). Daudi cells were purchased from ATCC. Daudi cells are naturally B2M− and are reported to be highly sensitive to NK cytolysis. All target cells were labeled with 1 uM CellTrace Violet (LifeTechnologies) to distinguish them from effectors in mixed cultures. Isolated NK cells were mi...

example 2

Characterization of Candidate shRNAs Against B2M and Effect of B2M Knockdown on NK Cell Killing of Primary Human T Cells

1. Materials and Methods

[0303]Five Mission-shRNA lentiviral transfer plasmids encoding different B2M targeting sequences were purchased from Sigma-Aldrich. Second-generation lentiviral vectors were produced in-house using Lenti-X 293T cells (ClonTech) and a triple transfection method (Lipofectamine 2000—Thermo-Fisher). T cells were prepared for lentiviral transduction by stimulating for 3 days with ImmunoCult anti-CD2 / CD3 / CD28 as in Example 1. Transduction was carried out in the presence of 5 uM polybrene (Sigma-Aldritch) and transduced cells were selected with puromycin (InVivoGen) beginning at 48 h post-transduction and concluding 72 h following drug addition. Selected cells were expanded for 5 days in IL-2 supplemented medium before a flow cytometric analysis of B2M surface expression to determine the extent of knockdown. Cultures receiving B2M shRNAs were used ...

example 3

Production and Characterization of CAR T Cells Utilizing shRNA to Reduce Cell Surface Expression of B2M

1. Materials and Methods

[0307]A number of constructs were prepared comprising an anti-CD19 CAR coding sequence and an shRNA against B2M. These are illustrated in FIG. 7A-7F and are provided in SEQ ID NOs: 18-23. CAR constructs 7007 and 7217 (SEQ ID NOs: 18 and 19) comprise the CAR coding sequence and the shRNA472 sequence in the same 5′ to 3′ orientation. CAR constructs 7008 and 7218 (SEQ ID NOs: 20 and 21) comprise the CAR coding sequence in the 3′ to 5′ orientation, and shRNA472 sequence in the 5′ to 3′ orientation (i.e., tail-to-tail). CAR constructs 7009 and 7219 (SEQ ID NOs: 22 and 23) comprise both the CAR coding sequence and the shRNA472 sequence in the 3′ to 5′ orientation. The 5′ and 3′ homology arms flanking the CAR coding sequence and the shRNA472 sequence have homology to regions upstream and downstream of the TRC 1-2 recognition sequence in the TRAC locus.

[0308]CAR T c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure provides nucleic acid molecules encoding an engineered antigen receptor, such as a chimeric antigen receptor or exogenous T cell receptor, and an inhibitory nucleic acid molecule, such as an RNA interference molecule. The present disclosure further relates to nucleic acids, DNA constructs, vectors, pharmaceutical compositions, genetically-modified cells, and methods of treatment that utilize the nucleic acid molecules of the invention.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a Continuation of U.S. application Ser. No. 16 / 678,600, filed Nov. 8, 2019, which is a Continuation of PCT / US2018 / 031674 filed May 8, 2018, which International Application was published by the International Bureau in English on Nov. 15, 2018, and application claims priority from U.S. Provisional Patent Application No. 62 / 503,060, filed May 8, 2017, and U.S. Provisional Patent Application No. 62 / 579,460, filed Oct. 31, 2017, which applications are hereby incorporated in their entirety by reference in this application.FIELD OF THE INVENTION[0002]The present disclosure relates to the field of molecular biology and recombinant nucleic acid technology. In particular, the present disclosure relates to nucleic acid molecules encoding an engineered antigen receptor, such as a chimeric antigen receptor or exogenous T cell receptor, and an inhibitory nucleic acid molecule, such as an RNA interference molecule. The present disclo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N5/0783C07K14/725C07K14/74C07K16/28C12N15/113
CPCC07K2319/00C12N2310/14C07K16/2803C07K14/7051C12N15/1138C12N5/0636C07K14/70539C12N2310/531C12N15/102C12N15/63C12N2320/31C12N2330/51C07K14/70592C12N2750/14143A61P35/00A61K39/4644A61K39/4611A61K39/4631
Inventor HUX, JOANNMARTIN, AARONJANTZ, DEREKBEARD, CLAYTON
Owner PRECISION BIOSCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap